Key points from article :
Kenai Therapeutics secured $82 million in funding to advance its allogeneic cell therapies for neurological diseases.
The funding will support clinical trials for their lead Parkinson's disease cell therapy candidate.
Uses iPSC technology to create cell therapies that replace neurons lost due to neurodegeneration.
Lead candidate, RNDP-001, is an allogeneic dopamine progenitor cell therapy derived from iPSCs.
RNDP-001 showed promising results in preclinical models and is expected to enter Phase 1 trials this year.
Kenai believes their approach has the potential to modify the course of Parkinson's disease.
The company is developing a pipeline of similar cell therapies for other neurological disorders.
